The greed of Big Pharma has left a massive 39.6% of all men and women in the United States affected by Cancer.
And while physicians have made considerable leaps forward as far as treatment goes, the unfortunate reality is that many people won’t be able to pay for a few of the top medication offered thanks to Big Pharma.
Lomustine is a drug cancer patients have been taking at home for more than 40 years.
It deals with a variety of cancer types, consisting of melanomas and lymphomas.
According to The Wall Street Journal, a capsule of Lomustine expense approximately $50 in 2012.
But things altered when a company called NextSource Biotechnology purchased the rights to Lomustine in 2013.
Since then, the cost of a single Lomustine pill has risen to an eye-watering $768.
That’s a 1,400% spike
Talking with The Independent, Duke University neuro-oncologist Henry Friedman specified:
“this is simply cost gouging. People are not going to be able to afford it, or they’re going to pay a great deal of cash and have monetary liability.”
It’s not just cancer drugs that have seen an absurd price walking either; in 2017, West-Ward Pharmaceuticals raised the rate of 6 medications utilized to deal with whatever from inflammation to diarrhea, cardiac arrest and bipolar disorder.
The prices of Big Pharma drugs all climbed up in between 75% and 430%
What makes this all the more troubling is the FDA’s persistence on squashing companies that intend to offer natural cancer treatments.
At the time, FDA Office of Enforcement director Douglas W. Stearn claimed that the clampdown was performed, in part, since such products may prevent people from seeking more “proper” treatment.
Following that clampdown, the FDA sent four letters to companies promoting marijuana-based products as having the capability to deal with cancer.
The argument was the same old story; such business is being vicious towards cancer clients and ought to for that reason be pinched.
No word yet on if or when FDA will use that same logic to clamp down on drug business that unjustly raises the rates of so-called “appropriate” medications.